SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-036700
Filing Date
2023-03-24
Accepted
2023-03-24 17:18:00
Documents
14
Period of Report
2023-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2310430d1_8k.htm   iXBRL 8-K 35420
2 EXHIBIT 1.1 tm2310430d1_ex1-1.htm EX-1.1 211312
3 EXHIBIT 5.1 tm2310430d1_ex5-1.htm EX-5.1 6291
  Complete submission text file 0001104659-23-036700.txt   483486

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA icpt-20230324.xsd EX-101.SCH 3055
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE icpt-20230324_lab.xml EX-101.LAB 34477
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE icpt-20230324_pre.xml EX-101.PRE 22610
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2310430d1_8k_htm.xml XML 3498
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35668 | Film No.: 23760812
SIC: 2834 Pharmaceutical Preparations